Ra Capital Management, L.P. - Jun 3, 2022 Form 4 Insider Report for Satsuma Pharmaceuticals, Inc. (STSA)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
STSA
Transactions as of
Jun 3, 2022
Transactions value $
$0
Form type
4
Date filed
6/7/2022, 05:31 PM
Previous filing
Jun 3, 2022
Next filing
Jun 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STSA Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jun 3, 2022 Common Stock 30K $3.46 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2 The shares subject to the option will vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting.
F3 Under Mr. Shah's arrangement with the Adviser, Mr. Shah holds the option for the benefit of the Fund. Mr. Shah is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest.

Remarks:

Mr. Rajeev Shah, a Managing Partner of the Adviser, serves on the Issuer's board of directors.